Pfizer Inc. (PFE), the world’s biggest drugmaker, said it stopped a clinical trial of its epilepsy medicine Lyrica after results showed it was as effective as a stand-alone therapy for certain-types of seizures. Lyrica generated more than $3 billion in sales last year for New York-based Pfizer, according to data collected by Bloomberg. The study aimed to show whether Lyrica worked without other drugs against partial seizures, the most common type experienced by people with the disorder.
